01778nas a2200289   4500000000100000008004100001260001600042653001700058653002400075653002000099653002200119653002800141653003500169653001700204100001300221700001600234700001300250700001300263700001600276700001800292700002000310700001600330245005500346856016700401520090600568022001401474       2020                            d  bElsevier BV10aParasitology10aInfectious Diseases10aschistosomiasis10ahealth inequities10aPreschool-aged children10amass drug administration (MDA)10aPraziquantel1 aFaust CL1 aOsakunor DN1 aDowns JA1 aKayuni S1 aStothard JR1 aLamberton PHL1 aReinhard-Rupp J1 aRollinson D00aSchistosomiasis Control: Leave No Age Group Behind  uhttps://reader.elsevier.com/reader/sd/pii/S1471492220301094?token=3C3D5E4231CCB709D3C4A7E7D170A458B72D492F85216915B309DE3F3C62364F59314A5A8B8328D523B3235924498D523 aDespite accelerating progress towards schistosomiasis control in sub-Saharan Africa, several age groups have been eclipsed by current treatment and monitoring strategies that mainly focus on school-aged children. As schistosomiasis poses a threat to people of all ages, unfortunate gaps exist in current treatment coverage and associated monitoring efforts, preventing subsequent health benefits to preschool-aged children as well as certain adolescents and adults. Expanding access to younger ages through the forthcoming pediatric praziquantel formulation and improving treatment coverage in older ages is essential. This should occur alongside formal inclusion of these groups in large-scale monitoring and evaluation activities. Current omission of these age groups from treatment and monitoring exacerbates health inequities and has long-term consequences for sustainable schistosomiasis control.  a1471-4922